Cancer Research

The landscape of modern oncology is rapidly shifting toward molecular precision, leaving behind the era of broad treatments that often fail to address specific genetic drivers. Patients with P-loop and alpha-C helix compressing mutations have long lacked targeted front-line options, often falling

A dual-action strategy utilizing small interfering RNA and small activating RNA provides a sophisticated framework for correcting the molecular imbalances found in complex human tumors. This innovative methodology represents a fundamental shift in modern oncology, moving away from universal,

A significant challenge in oncology is that nearly one-quarter of breast cancer diagnoses involve aggressive HER2-positive tumors that require immediate and effective neoadjuvant therapy. This aggressive subtype is defined by an overabundance of the HER2 protein, which promotes the rapid growth of

Metastatic spinal tumors originating from lung cancer often cause debilitating symptoms including chronic pain, pathological fractures, and potential paralysis. In the current medical landscape of 2026, clinicians face the daunting task of managing these secondary growths with extreme precision.

The use of liquid biopsies for rapid genomic analysis provides a vital alternative for frail pediatric patients who cannot survive the trauma of traditional invasive diagnostic procedures. Recent breakthroughs in pediatric oncology at Addenbrooke’s Hospital have fundamentally changed the approach

Industry analysts project that global peak annual sales for the pancreatic cancer treatment daraxonrasib could eventually reach eleven point five billion dollars. This staggering figure reflects the immense medical need for effective therapies targeting RAS-mutated cancers, which have long remained